Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Science & Research

  • Print
  • Share
  • E-mail
-

Scientific Integrity at FDA

 

 Scientific and professional staff working to protect and promote public health

FDA is launching this web page as a single source to find and reference all FDA principles, policies, and procedures related to scientific integrity. A recent Agency-wide policy presents FDA's key principles of scientific integrity and highlights important procedures and policies FDA is implementing to further those principles.

Science—both its quality and integrity—is the touchstone of everything we do at FDA. In carrying out our mission to protect and promote the public health, FDA needs the best scientific and technological information available to make decisions on the products we regulate. Critical to our ability to reach sound decisions and to retain the public's trust are high-quality data and a scientific review process that is thorough and unbiased.

Our scientific experts may hold differing views on what they conclude from data. There may be multiple options that can be considered during policy development or regulatory decision-making. However, in reaching our conclusions through a deliberative scientific process, FDA strives to present an evaluation and analysis of the data--including uncertainties--in an unbiased manner.  
 
FDA has a long and continuing history of promoting an environment of robust scientific debate, where the integrity of information is ensured, all views are carefully considered, and scientific decisions are protected from political influence.  In 2009, we established FDA's Office of Scientific Integrity (OSI).  OSI works to:
 
1. ensure that FDA's policies and procedures are current and applied across the Agency;
2. resolve scientific disputes that may arise internally or externally and that are not resolved
    at the Agency's Center levels; and
3. advise the Chief Scientist and other senior FDA leaders on appropriate responses.
 
To ensure that we maintain a highly skilled scientific staff capable of addressing the regulatory challenges presented by new areas of science, the Agency recently stood up the Office of Scientific Professional Development.  And in response to a 2009 directive from the President’s Office of Science and Technology Policy to develop policies and procedures as a means of ensuring scientific integrity in agency decision-making, FDA also recently issued an Agency-wide policy that presents key principles of scientific integrity and highlights important procedures and policies we have implemented at FDA that advance those principles. 
 
FDA Centers are implementing and following the general principles and procedures outlined in this policy.  The policies, procedures, and initiatives related to or supporting scientific integrity at the Agency listed below will be updated regularly.

 

-
-
 

Contact FDA

301-796-4880
Office of the Chief Scientist

FDA White Oak Campus - Building 32

10903 New Hampshire Ave

Silver Spring, MD 20993
-
-